CompletedPhase 2

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

United States262 participantsStarted 2024-10-01

Plain-language summary

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults ≥ 18 years of age * BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated) * A stable body weight for 3 months prior to Screening (±5% body weight change) Exclusion Criteria: * Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome * Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening * Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier) * History of type 1 diabetes mellitus or T2DM

What they're measuring

Percent change in body weight from baseline to week 26

Timeframe: 26 weeks

Weight loss ≥ 5% from baseline weight to week 26

Timeframe: 26 weeks

Trial details

NCT IDNCT06595238

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-08-08

View on ClinicalTrials.gov More Obesity or Overweight trials